Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H14NO5P |
| Molecular Weight | 259.1956 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOP(=O)(CC)OC1=CC=C(C=C1)[N+]([O-])=O
InChI
InChIKey=XXUJMEYKYHETBZ-UHFFFAOYSA-N
InChI=1S/C10H14NO5P/c1-3-15-17(14,4-2)16-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3
| Molecular Formula | C10H14NO5P |
| Molecular Weight | 259.1956 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://dxline.ru/drugs/arminCurator's Comment: description was created based on several sources, including:
http://www.medicinform.net/spravka/b1/b1_82.htm
https://ru.wikipedia.org/wiki/Армин
Sources: http://dxline.ru/drugs/armin
Curator's Comment: description was created based on several sources, including:
http://www.medicinform.net/spravka/b1/b1_82.htm
https://ru.wikipedia.org/wiki/Армин
Armin is irreversible cholinesterase inhibitor. It acts considerably longer and stronger than reversible cholinesterase inhibitors. It is used for glaucoma treatment. Armin might be used in combination with other antiglaucoma drugs. Known adverse effects are: hypersalivation, sweating, dyspepsia, frequent urination, blurred vision, headache, dizziness, twitching of the tongue and skeletal muscles, nausea, vomiting.
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 9.0 |
inconclusive | |||
Page: 78.0 |
no | |||
Page: 73.0 |
no | |||
Page: 70.0 |
no | |||
Page: 4.0 |
yes | |||
Page: 3.0 |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 11 | 69 |
no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 78.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Treatment effectiveness in open-angle glaucoma using aqueous and prolonged-action armin solutions]. | 1980-05-01 |
|
| [Effect of nibuphine, pilocarpine and armine on the size of the blind spot and angioscotoma in patients with primary glaucoma]. | 1971-09-01 |
|
| [Use of armin in glaucoma]. | 1960 |
|
| [Clinical evaluation of armin]. | 1958-07-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://dxline.ru/drugs/armin
1-2 drops 2-3 times per daily
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:53 GMT 2025
by
admin
on
Mon Mar 31 18:44:53 GMT 2025
|
| Record UNII |
H39MRI1X2O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Armine (chemical)
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
D001138
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106820
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
546-71-4
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
H39MRI1X2O
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
DTXSID5048843
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY | |||
|
66067
Created by
admin on Mon Mar 31 18:44:53 GMT 2025 , Edited by admin on Mon Mar 31 18:44:53 GMT 2025
|
PRIMARY |